The stock price of Adverum Biotechnologies Inc (NASDAQ: ADVM) has plunged by -7.36 when compared to previous closing price of 11.00, but the company has seen a -10.22% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-23 that Here is how Adverum Biotechnologies (ADVM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
Is It Worth Investing in Adverum Biotechnologies Inc (NASDAQ: ADVM) Right Now?
ADVM has 36-month beta value of 0.85. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ADVM is 14.98M, and currently, short sellers hold a 5.94% ratio of that float. The average trading volume of ADVM on April 25, 2024 was 279.77K shares.
ADVM’s Market Performance
The stock of Adverum Biotechnologies Inc (ADVM) has seen a -10.22% decrease in the past week, with a -31.84% drop in the past month, and a 12.10% gain in the past quarter. The volatility ratio for the week is 6.43%, and the volatility levels for the past 30 days are at 6.33% for ADVM. The simple moving average for the last 20 days is -18.14% for ADVM stock, with a simple moving average of -26.59% for the last 200 days.
Analysts’ Opinion of ADVM
Many brokerage firms have already submitted their reports for ADVM stocks, with Truist repeating the rating for ADVM by listing it as a “Buy.” The predicted price for ADVM in the upcoming period, according to Truist is $4 based on the research report published on July 07, 2022 of the previous year 2022.
SVB Leerink gave a rating of “Mkt Perform” to ADVM, setting the target price at $5 in the report published on May 03rd of the previous year.
ADVM Trading at -37.14% from the 50-Day Moving Average
After a stumble in the market that brought ADVM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.69% of loss for the given period.
Volatility was left at 6.33%, however, over the last 30 days, the volatility rate increased by 6.43%, as shares sank -27.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.79% lower at present.
During the last 5 trading sessions, ADVM fell by -10.22%, which changed the moving average for the period of 200-days by -45.80% in comparison to the 20-day moving average, which settled at $12.25. In addition, Adverum Biotechnologies Inc saw 35.36% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADVM starting from Lupher, Jr. Mark L., who purchase 130,000 shares at the price of $1.35 back on Feb 07 ’24. After this action, Lupher, Jr. Mark L. now owns 130,000 shares of Adverum Biotechnologies Inc, valued at $175,500 using the latest closing price.
Scopa James Paul, the Director of Adverum Biotechnologies Inc, purchase 100,000 shares at $1.35 during a trade that took place back on Feb 07 ’24, which means that Scopa James Paul is holding 100,000 shares at $135,000 based on the most recent closing price.
Stock Fundamentals for ADVM
Current profitability levels for the company are sitting at:
- -34.39 for the present operating margin
- -2.49 for the gross margin
The net margin for Adverum Biotechnologies Inc stands at -32.55. The total capital return value is set at -0.84. Equity return is now at value -88.43, with -48.68 for asset returns.
Based on Adverum Biotechnologies Inc (ADVM), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at -1.21. The debt to equity ratio resting at 0.9. The interest coverage ratio of the stock is 103.16.
Currently, EBITDA for the company is -118.15 million with net debt to EBITDA at -0.0. When we switch over and look at the enterprise to sales, we see a ratio of 58.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.13.
Conclusion
To put it simply, Adverum Biotechnologies Inc (ADVM) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
